Bibliography
- Sloan PA, Babul N. Extended-release opioids for the management of chronic non-malignant pain. Expert Opin Drug Deliv 2006;3:489-97
- Chou R, Fanciullo GJ, Fine PG, Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10:113-30
- Sloan PA, Hamann SR. Ultra low-dose opioid antagonists to enhance opioid analgesia. J Opioid Manag 2006;2:295-304
- Efficacy and safety of tapentadol extended release. Expert Opin Pharmacother 2010;11(11):1787-804
- Tzschentke TM, De Vry J, Terlinden R, Tapentadol HCL. Drugs Future 2006;31:1053-61
- Hartrick CT. Tapentadol immediate release for the relief of moderate-to-severe acute pain. Expert Opin Pharmacother 2009;10:2687-96
- Wade WE, Spruill WJ. Tapentadol hydrochloride: a centrally acting oral analgesic. Clin Ther 2009;31:2804-18
- Terlinden R, Kogel BY, Englberger W, Tzschentke TM. In vitro and in vivo characterization of tapentadol metabolites. Methods Find Exp Clin Pharmacol 2010;32:31-8
- Terlinden R, Ossig J, Fliegert F, Absorption, metabolism, and excretion of 14C-labeled tapentadol HCL in healthy male subjects. Eur J Drug Metab Pharmacokinet 2007;32:163-9
- Kleinert R, Lange C, Steup A, Single dose analgesic efficacy of tapentadol in postsurgical dental pain: the results of a randomized, double-blind, placebo-controlled study. Anesth Analg 2008;107:2048-55
- Daniels SE, Upmalis D, Okamoto A, A randomised, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain. Curr Med Res Opin 2009;25:765-76
- Hale M, Upmalis D, Okamoto A, Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study. Curr Med Res Opin 2009;25:1095-104
- Pergolizzi J, Boger RH, Budd K, Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 2008;8:287-313
- Etropolski M, Shapiro A, Okamoto C, Efficacy and safety of tapentadol ER for diabetic peripheral neuropathic pain: results of a randomized-withdrawal, double-blind, placebo-controlled phase III study. Neurology 2009;72:A217-8
- Christoph T, De Vry J, Tzschentke TM. Tapentadol, but not morphine, selectively inhibits disease-related thermal hyperalgesia in a mouse model of diabetic neuropathic pain. Neuroscience Lett 2010;470:91-4
- NUCYNTA(TM) (tapentadol) CII immediate release tablets now available for relief of moderate to severe acute pain ((2010). Available from: www.Nucynta.com /nucynta/dosing-and-administration.html [Accessed May 2010]